Organogenesis Holdings Inc (ORGO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.08 Million) by net assets ($385.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Organogenesis Holdings Inc stock valuation for the company's overall valuation and market capitalisation.
Organogenesis Holdings Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Organogenesis Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Organogenesis Holdings Inc ranked by their cash flow conversion efficiency. Explore Organogenesis Holdings Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Signature International Bhd
KLSE:7246
|
0.018x |
|
Sagar Cements Limited
NSE:SAGCEM
|
0.048x |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
0.004x |
|
GAEC Educacao SA
SA:ANIM3
|
0.100x |
|
TBI Motion Technology Co Ltd
TW:4540
|
-0.091x |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
-0.254x |
|
Sanstar Ltd
NSE:SANSTAR
|
0.064x |
|
Mulpha International Bhd
KLSE:3905
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Organogenesis Holdings Inc from 2001 to 2024. View Organogenesis Holdings Inc (ORGO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $385.32 Million | $14.21 Million | 0.037x | -66.76% |
| 2023-12-31 | $278.66 Million | $30.92 Million | 0.111x | +18.57% |
| 2022-12-31 | $265.67 Million | $24.86 Million | 0.094x | -63.56% |
| 2021-12-31 | $241.34 Million | $61.98 Million | 0.257x | +566.27% |
| 2020-12-31 | $141.81 Million | $5.47 Million | 0.039x | +106.39% |
| 2019-12-31 | $55.58 Million | $-33.53 Million | -0.603x | +53.28% |
| 2018-12-31 | $47.04 Million | $-60.74 Million | -1.291x | -65496.73% |
| 2017-12-31 | $298.01 Million | $-586.60K | -0.002x | -5.07% |
| 2016-12-31 | $300.11 Million | $-562.23K | -0.002x | -100.00% |
| 2015-12-31 | $-162.00 | $-10.19 Million | 62919.753x | +9389980.80% |
| 2001-12-31 | $-2.08 Million | $-1.40 Million | 0.670x | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more